Find Clinical Trials

Inclusion Criteria: * Confirmed histologic diagnosis of invasive adenocarcinoma of the breast; * Stage T1-4N+M0 breast cancer (i.e., stages II and III); * Breast MRI showing no extracapsular extension of lymph node involvement; * The standard neoadjuvant chemotherapy regimen has been deemed ineffective after two cycles, with disease assessed as stable (SD) or progressive (PD) according to RECIST 1.1 criteria; * ECOG performance status score of 0-2; * Screening laboratory values must meet the following criteria: i. White blood cells (WBCs) ≥ 2000/μL ii. Absolute neutrophil count (ANC) ≥ 1500/μL iii. Platelets ≥ 100 x 103/μL iv. Hemoglobin ≥ 11.0 g/dL v. Serum creatinine ≤ 2 mg/dL (or glomerular filtration rate ≥ 40 ml/min) vi. AST ≤ 2.5 x upper limit of normal (ULN) vii. ALT ≤ 2.5 x ULN viii. Total bilirubin within normal limits (except subjects with Gilbert\'s syndrome, who must have total bilirubin \< 3.0 mg/dL) ix. INR ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulant(s) x. Negative HIV screening test xi. Negative screening tests for Hepatitis B and Hepatitis C. Patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator. Exclusion Criteria: * Evidence of metastatic disease; * Known additional malignancy that is progressing or has required active treatment within the past 3 years； * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug； * Patients with other concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study； * Pregnancy or breastfeeding.

Inclusion Criteria: 1. Cohort-specific inclusion for male and female patients. a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following: * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and/or other breast cancer interventions. * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years. * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years. b. Cohort B (prior cranial radiation) * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors. * Life expectancy \> 6 months 2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study. 3. ≥18 years of age 4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment. 5. Able to provide informed consent. 6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires. 7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes. * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance. Exclusion Criteria: 1. Cohort-specific exclusion for male and female patients: 1. Cohort A (no prior cranial radiation) * History of or current presence of primary brain tumors or brain metastases. 2. Cohort B (prior cranial radiation) * Diagnosed with high grade glioma. 2. Unwilling to undergo neuropsychological assessments necessary for the study. 3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy. a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy. 4. History of suspected hypersensitivity to riluzole or to any of its excipients. 5. Patients taking or planned to take medications/substances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole. 6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN) 7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.

Inclusion Criteria: Age above 18 years. Diabetic type ll. Admitted for more than 48 hours. Exclusion Criteria: Type 1 Diabetes Mellitus. Age under 18 years Readmission in intensive care unit. Adimssion for less than 48 hours

Inclusion Criteria: * Aged 18 years and older * Type 2 diabetes diagnosed for at least 12 months * Established on an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, or have been offered these therapies previously. * Treatment with insulin therapy for at least 6 months * HbA1c ≤ 15% (140 mmol/mol) analysis from local laboratory or equivalent * Willing to wear study devices and follow study instructions * Capacity to consent to participate in the study Exclusion Criteria: * Type 1 diabetes * Current use of insulin pump * Current use of any closed-loop system * Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician * Known or suspected allergy against insulin * Medically documented allergy towards the adhesive * Pregnancy, planned pregnancy, or breast feeding * Severe visual impairment * Severe hearing impairment * Medically documented allergy towards the adhesive (glue) of plasters * Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor * Illicit drugs abuse * Prescription drugs abuse * Alcohol abuse

Inclusion Criteria: * Diagnosis of knee osteoarthritis according to ACR knee osteoarthritis diagnostic criteria * Being in stage 2 or 3 according to Kellgren-Lawrence radiological staging criteria * To be 18 years of age or older * Being a reader-writer * Having read and signed the informed consent Exclusion Criteria: * History of major psychiatric illness * Having malignant disease * Having chronic infectious or other rheumatologic diseases * Serious knee trauma or surgical operation in the last 6 months * Having collagen tissue disease * History of peripheral vascular disease or neuropathy * Being in stage 4 according to Kellgren Lawrence radiologic staging criteria * To have received a physiotherapy program for the relevant knee in the last 3 months

Inclusion Criteria: 1. Diagnosed as cirrhosis 2. Previous or present endoscopic diagnosis of esophageal and gastric varices bleeding. 3. Child -Pugh score C (≤13) or MELD≤18. 4. Enhanced image measurement of liver volume ≤1000cm3. 5. Have indications for TIPS treatment. 6. Researchers believe that patients have the ability to comply with the research plan. 7. Sign the informed consent form Exclusion Criteria: 1. Malignant tumor (including hepatocellular carcinoma) or other diseases that will shorten the life span of patients. 2. Cavernous portal vein 3. Non-cirrhotic portal hypertension (Budd-Chiari syndrome, extrahepatic portal vein obstruction, idiopathic portal hypertension, etc.) 4. Spontaneous dominant hepatic encephalopathy 5 congestive heart failure or severe valvular heart failure 6\. Uncontrollable systemic infection or inflammation 7. Severe pulmonary hypertension 8. Severe renal insufficiency (except hepatogenic renal insufficiency) 9. Rapidly progressing liver failure 10. Contrast agent allergy 11. History of liver transplantation or allogeneic organ transplantation 12. Have a history of TIPS or shunt operation. 13. Pregnancy or lactation 14. Poor compliance 15. Participate in another clinical study.

Inclusion Criteria: * Women aged 18 to 75 years * Planning to initiate HRT/HC within next 30 days Exclusion Criteria: * Gynecological, endocrinological or other disease affecting the ovarian cycle * FEV1 \< 60% of expected or \< 1.5L * Current hormonal medication * Pregnancy

Inclusion Criteria: * Edinburgh Postnatal Depression Scale (EPDS) score 11-18 * ≥age 18 * Access to the internet Exclusion Criteria: * Thoughts of self-harm≥2 on EPDS item 10 * Do not understand Danish language, * Substance abuse or dependence * Alcohol abuse, defined as a weekly consumption of alcohol exceeding ten units, * Physical condition requiring frequent hospitalization like dialysis, chemotherapy, or blood transfusion, * A diagnosis of schizophrenia or other psychotic disorders.

Inclusion Criteria: * Patients who are 18 years of age or older * Patients undergoing mastectomy with or without axillary surgery, with or without reconstruction surgery at UCMC for breast cancer or high-risk of breast cancer. Patients with high-risk of breast cancer are those who have atypical/precancerous breast lesion(s), genetic mutation with increased risk of cancer (e.g., BRCA1, BRCA2 etc..) and/or a strong family history of breast cancer in the opinion of the investigator. Exclusion Criteria: * Patients undergoing only a partial mastectomy or tissue-based reconstruction. * Non-English speaking. * Patients who are pregnant. * Patients with an allergy to local anesthetics * Except: patients with allergies only to topical anesthetics may be included. * Patients with a preoperative acute or chronic pain disorder with an opioid prescription that has been prescribed within 30 days of surgery. Patients who have not filled such a prescription or who state they have not taken the medications prescribed, may be eligible on a case-by-case basis per investigator judgement. * Patients with a history of opioid use disorder. * Inability to provide informed consent. * Patients who otherwise in the opinion of the Investigator are not good candidates for participation (e.g., deemed unreliable for follow-up).

Inclusion criteria LED intervention * Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes). * Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤ 80 mmol/mol. To allow for the day-to-day variation in HbA1C and differences between point of care laboratory tests, -2 or +2 mmol/mol in the HbA1C result will be allowed in the current criteria if one of them is between or equal to 42-80mmol/mol. * Aged 12 to 17 years old. * BMI ≥981st centile (+2 SD) for age and sex (UK90 growth reference data). * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to engage in and commit to low energy diet, FR and weight management phases including follow-up and attending study visits. LED Intervention Interviews The same interview inclusion criteria for LED intervention, with the following additional requirements: Patients: * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to take part in a qualitative interview alongside a parent/carer. Relative/Carer: * A relative/carer for a young person meeting the above LED participant eligibility criteria. * Informed consent from the relative/carer to participate in the interview. * Willing to take part in a qualitative interview alongside the young person. Non-LED Qualitative Interview only participants * Diagnosis of T2DM (defined as an HbA1C ≥48mmol/mol, in the absence of features of type 1 or monogenic/syndromic diabetes). * Current HbA1C ≥48 (or ≥42 on antidiabetic medication) and ≤80 mmol/mol. * Aged 12 to 17 years old. * BMI ≥91st centile (+2 SD) for age and sex (UK90 growth reference data). * Informed consent: * Received from the young person (age 16-17) OR * Received from young person's parent/carer, with patient assent (age 12-15). * Willing to take part in a qualitative interview alongside a parent/carer only. HCPs * Registered HCP. * Experience of delivering this trial to the adolescents. * Willing to take part in a qualitative interview about undertaking motivational interviewing training and conducting/delivering the LED intervention study. Exclusion criteria LED intervention * HbA1C greater than 82mmol/mol (to allow for the variation in HbA1c differences). * Presence of diabetes-related autoantibodies, as per local centre guidelines. * Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome. * Secondary diabetes (post bone marrow transplant/chemotherapy). * Significant psychiatric co-morbidity. * Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10). * Any other condition which, in the opinion of the study investigator, would make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt). * Participation in another interventional trial within 6 months. * Informed consent and/or assent not received. * Pre-existing retinopathy. * Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose. * Previous scoliosis repair. Non-LED Qualitative Interview only participants * HbA1C greater than 80mmol/mol. * Presence of diabetes-related autoantibodies, as per local centre guidelines. * Confirmed mono-genetic cause of obesity (e.g. SIM1 mutation) or diabetes-associated syndrome such as Prader-Willi syndrome, Bardet-Biedl or Wolfram's syndrome. * Secondary diabetes (post bone marrow transplant/chemotherapy). * Significant psychiatric co-morbidity. * Breastfeeding, pregnant or planning to conceive during the LED and FR phases (female participants will be advised on need for effective contraceptive methods during the 12-month study period, section 5.1.1.10). * Any other condition which, in the opinion of the study investigator, would either make it inappropriate to undertake a period of LED. (All reasons for not approaching patients will be recorded and analysed anonymously. Cases can be discussed with the core study group if there is doubt). * Participation in another interventional trial within 6 months. * Informed consent and/or assent not received. * Pre-existing retinopathy. * Dietary avoidance (including, but not limited to, due to allergies, intolerances, religious reasons and lifestyle choices) to any ingredients in the meal replacement products, including lactose. * Previous scoliosis repair. HCPs • None.

Inclusion Criteria: Patients eligible for inclusion in this trial must meet all of the following criteria: 1. Patients ≥ 18 years and \< 80 years 2. Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features 3. Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites 4. INR ≤ 1.5 5. Ability to understand the nature of the trial and the trial related procedures and to comply with them Exclusion Criteria: Patients eligible for this trial must not meet any of the following criteria: 1. Treatment refractory or recurrent ascites at the time of study inclusion 2. Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C \< 14 points or Child-Pugh class B \>7 with active bleeding at initial endoscopy or hepatic venous pressure gradient \[HVPG\] \> 20 mmHg at the time of bleeding) 3. Budd-Chiari syndrome 4. Portal vein thrombosis (PVT) 5. Spontaneous bacterial peritonitis (SBP) 6. Uncontrolled systemic infection (defined as an increase of \> 20% if inflammatory parameters \[C-reactive protein, procalcitonin, leukocytes\] and/or sepsis as a reason for development of ascites 7. Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease) 8. Clinical significant cardiac disease (NYHA ≥II) 9. Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves) 10. Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE) 11. Reduced left ventricular ejection fraction ≤50% 12. Pulmonary hypertension (mean pulmonary arterial pressure \> 45 mmHg) 13. Bilirubin \> 3 mg/dl 14. Obstructive cholestasis 15. Hepatorenal syndrome type AKI (HRS-AKI) 16. Acute on chronic liver failure 17. Benign liver tumor within the potential puncture tract 18. Patient after liver transplantation 19. Prior TIPS implantation 20. Ongoing and/or recurrent hepatic encephalopathy (grade \>II) 21. Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment 22. New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months 23. Untreated chronic hepatitis C virus (HCV) infection 24. Life expectancy \<1 year 25. Pregnant or breastfeeding women 26. Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study 27. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed 28. Person who is in a relationship of dependence/employment with the sponsor or the investigator

Inclusion Criteria: * Woman and its male partner aged 18 years old and older * Couple understanding, speaking and reading French * Couple giving their informed consent to participate voluntarily Exclusion Criteria: * Woman without male partner * Woman admitted to intensive care after giving birth * Couple whose newborn died peripartum * Couple who have had a medical abortion or fetal death in utero for the current pregnancy * Woman and/or male partner refusing to participate in the study * Woman and/or male partner not speaking French * Woman and/or male partner in the incapacity to answer the questionnaires * Woman and/or male partner under guardianship or conservatorship, deprived of liberty, or in the custody of correctional authorities

Inclusion Criteria: 1. Aged 18-45 years (including 18 and 45), no gender restriction; 2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V); 3. Outpatients or inpatients; Hamilton Depression Rating Scale 17-item (HAMD-17) score ≥ 14; Mood Disorder Questionnaire (MDQ) screening negative to exclude bipolar disorder patients; and Clinical Global Impressions-Severity (CGI-S) score ≥ 4; 4. Maintained on antidepressant treatment for at least 4 weeks or not using antidepressant treatment; 5. Written informed consent obtained from the patient. Exclusion Criteria: 1. Diagnosed with other mental disorders, including schizophrenia, bipolar disorder, alcohol or substance abuse/dependence, eating disorders, etc.; 2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness; 3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury; 4. Suffering from conditions with high exercise risk, such as hypertension or heart disease; 5. Currently undergoing systematic psychological therapy; 6. In the 3-minute step test, males with a recovery heart rate more than131 and females with a recovery heart rate more than 140; 7. Physically restricted individuals unable to participate in physical exercise; 8. Physical Activity Readiness Questionnaire (PAR-Q) score ≥ 2; 9. Pregnant women or individuals with contraindications to MRI examinations; 10. Individuals with severe suicidal tendencies or at risk of harming others.

Inclusion Criteria: * Age 18-75 years * Have a properly documented hypertension by abpm, hbpm, unattended office blood pressure measurement or carefully performed office measurement. * Has a physician who feels an urge to exclude or diagnose EHT for one or more of the following reasons * resistant hypertension AND/OR * hypokalemia, spontaneous or diuretic-induced AND/OR * history or physical examination suggestive of endocrine hypertension * Willingness and ability to give informed consent Exclusion Criteria: * White-coat hypertension * Known renal artery stenosis * Known licorice abuse * Known familial form of endocrine hypertension * Cardiovascular event (myocardial infarction, cerebrovascular event) \< 6 months \[Y/N\] * Hypertensive crisis \< 6 months * eGFR \< 50 ml/min/1,73m2 * Liver failure * Known severe valvular or structural heart disease (excluding left ventricular hypertrophy) * NYHA class III or IV heart failure or known reduced left ventricular function (ejection fraction (EF) \<30%) * EKG demonstrating significant pathology (e.g. myocardial infarction, atrial fibrillation, or any other cardial condition prohibiting start of study medication) * Life expancy \< 1 year * For women, current pregnancy or unprotected intercourse

Inclusion Criteria: 1. Breast cancer confirmed by pathology； 2. Tumor \<5 cm, TNM stage 0-II； 3. Single Port Endoscopic or traditional open surgery; (4)20 to 70 years old female patients. Exclusion Criteria: 1. Bilateral breast cancer; 2. Reconstruction after breast conserving surgery ; 3. Basic information is not complete； 4. Breast conserving surgery was converted to modified radical resection or subcutaneous adenoidectomy.

Key Inclusion Criteria: * Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening. * Part A (SAD) and Part B (Food/PPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with BMI of ≥ 19 and \< 30 kg/m\^2, and no significant medical history. Individuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose. * Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg/m\^2 and \< 45 kg/m\^2 with a total body weight \> 50 kg, and nondiabetic (HbA1c \< 6.5%). Eligible individuals will also be individuals with stable body weight (\< 5% change) for 90 days prior to screening visit based on individual report. * Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \< 30 kg/m\^2 and treated with diet and/or exercise, and/or metformin monotherapy. Key Exclusion Criteria: * Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes \[with the exception of T2DM for individuals included in Part D only\]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment. * Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening. * Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia). * Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator. * History of syncope, palpitations, or unexplained dizziness. * Active, or history of, significant cardiac disease or conduction abnormality * History of implanted defibrillator or pacemaker. * Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic steroids, immunosuppressant therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies). * Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Inclusion Criteria: * Clinician diagnosis of asthma for ≥1 year; * Age at enrollment--18-75 years old inclusive; * One or more AEXs that occurred \&lt; 12 months prior to enrollment. An AEX is defined as an asthma deterioration that either requires 72 hours or more of an oral or parenteral steroids OR a hospital stay for more than 24 hours for asthma. In the case of patients on biologics for asthma, the exacerbation must have also occurred after at least 6 months of biologic therapy; * Currently prescribed an ICS/LABA containing preparation containing at least the lowest dose of ICS described in Table 2 as regular daily maintenance therapy for at least one month; * Has a rescue SABA containing inhaler that they have used on average at least once a month. * Able to provide consent in English for the feasibility study or in English or Spanish for the full study. Exclusion Criteria: * Life expectancy \&lt;2 years; * COPD diagnosis unless: a) they were a never smoker; OR b) former smoker with normal pulmonary function tests (PFT; FEV1/FVC ratio of \&gt;70%); OR c) current smoker with normal PFTs within 24 months of enrollment; OR d) current or former smoker with obstruction on PFTs (FEV1/FVC ratio of \&lt;70% but who demonstrates BOTH \&gt;12% acute bronchodilator reversibility AND a normal diffusing capacity both within 24 months of enrollment (criteria successfully used in PREPARE); * Use of single inhaler product that contains an ICS, LAMA and LABA or one containing both LABA and LAMA within 1 month of enrollment; * Use of current biologic for less than 6 months; * Known allergy to any of the components of the intervention; * Coexisting lung disease (e.g. Cystic Fibrosis, connective tissue disease (unless asthma preceded diagnosis of connective tissue disease by at least 2 years), prematurity-born at 32 weeks or sooner, organ transplantation, bronchiectasis, sarcoid, and obliterative bronchiolitis, among others) * Has been in an asthma drug treatment trial in past 60 days or within 5 half-lives, whichever is longer, prior to study visit. * Living in household with someone already enrolled in the study. * Using daily or every other day oral corticosteroids for asthma or any other condition * An AEX in the prior 4 weeks * History of bronchial thermoplasty in prior 6 months * Poorly or uncontrolled atrial fibrillation * Not on stable asthma medications for at least 1 month prior to enrollment * Using doses of ICS/LABA lower than the minimum below: * Budesonide 320 ug, * Fluticasone Advair Diskus/ Wixela 200-250 ug Advair HFA 180-230ug Airduo 110-113 ug Breo 100 ug * Mometasone 200 ug

Inclusion Criteria: 1. Sign a written informed consent form; 2. Male or female ≥ 18 years old; 3. Patients with gastrointestinal cancer or breast cancer who are diagnosed with cancer by pathology will receive capecitabine treatment for the first time according to the label; 4. The performance status of the Eastern Cancer Collaboration Group is 0-2; 5. Palliative or adjuvant chemotherapy with capecitabine (combination or monotherapy, minimum daily total dose of capecitabine 2000 mg/m\^2); 6. Expected lifespan ≥ 3 months; 7. Laboratory requirements: platelet count ≥ 100 × 10\^9/L, white blood cell count\&amp;amp;gt;3.0 × 10\^9/L, hemoglobin ≥ 10.0 g/dL, normal liver and kidney function; 8. Adequate contraception. Exclusion Criteria: 1. Previous use of capecitabine or liposome doxorubicin or any other tyrosine kinase inhibitor that may induce HFS (such as sorafenib, sunitinib, and apatinib) for chemotherapy; 2. The initial dose of capecitabine is less than 800mg/m\^2; 3. Radiation therapy or surgery should be performed within 4 weeks before the start of treatment; 4. Skin diseases that may interfere with clinical trial results; 5. Known drug/alcohol abuse; 6. Pregnant women or lactating patients; 7. Participate in another clinical trial and the patient has received the investigational drug within the last 30 days prior to the start of treatment (i.e. follow-up in the previous trial was not exclusive); 8. Known patients who are afraid of electroacupuncture stimulation or allergic to stainless steel needles or any component of capecitabine; 9. Receive any acupuncture and moxibustion treatment ,there is lymphedema in the area stimulated by acupuncture; 10. Patients with any chemotherapy- or radiotherapy-related toxicities that have not subsided to grade 2 or lower will be excluded, except for stable sensory neuropathy. 11. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss, will also be grounds for exclusion.

Inclusion Criteria: * 18 years * candidates for surgery * candidates for adjuvant and/or neoadjuvant treatment Exclusion Criteria: * 0 to 17 years old * severe language deficits * severe barriers * Patients unable to understand and express informed consent

Inclusion Criteria: * Pre-eclamptic patient according to the criteria defined by SFAR 2020. * Indication of organised or semi-urgent cesarean section (Green or Orange code). * Adult patient, benefiting from a social security system. * Oral non-opposition to participation in the study. Exclusion Criteria: * Urgent Cesarean (Red code). * Patient refusal. * Patient does not understand French. * Individual protection measures : guardianship, curatorship.